PSMA PET scan for liver cancer staging
Part of Cancer, Digestive system clinical trials.
This trial tests if a special PET scan (PSMA PET) can better stage liver cancer that has not been treated yet and is at a moderate to advanced stage (BCLC B or C). It may help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a patient in the VA healthcare system.
- You are 18 years or older.
- You have been diagnosed with liver cancer (hepatocellular carcinoma) and have not had any treatment for it yet.
- Your liver cancer is at stage BCLC B or BCLC C (moderate to advanced).
- You do not have severe kidney problems or a contrast allergy that would prevent you from getting a standard CT or MRI scan.
- You have not had any other active cancer (except non-melanoma skin cancer) in the past 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
This trial tests a new imaging technique that may help doctors see liver cancer more clearly. It uses a special tracer that targets a protein found on many liver cancer cells. This could help with diagnosis and monitoring.
This trial uses a special PET scan (68Ga-FAPI) to see how well systemic therapy is working in people with advanced liver cancer that can't be removed by surgery. The goal is to find a better way to measure treatment effectiveness.
This trial tests a new PET imaging method that uses two different tracers to find and stage liver cancer (HCC) or neuroendocrine tumors (GEP-NET) more accurately. It may help doctors decide on the best treatment for you.
This study tests a new type of PET/CT scan (called PSMA) that may help doctors see liver cancer (HCC) better. The scan takes detailed images to track how the cancer behaves, which could help choose the best treatment.
This trial tests whether a new PET imaging agent (GPC3-targeted) can find liver cancer as well as or better than enhanced MRI. It may help diagnose hepatocellular carcinoma (the most common type of liver cancer) more accurately.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.